ClinicalTrials.gg
RecruitingNCT07320339Updated Jan 6, 2026

The Aim of the Study is to Examine the Variation in Blood Pressure Between an Optimal Measurement (According to Established Guidelines in the Literature - Per Guidelines) and a 'Common' Measurement (Used by Nursing Teams - Per Common Practice) Among Women of Reproductive Age With and Without Hyperte

An interventional study of blood pressure measurement in Blood Pressure Measurement in Pregnancy, sponsored by Hillel Yaffe Medical Center. Recruiting at 1 site in Israel. Open to female participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-06.

Sponsored by Hillel Yaffe Medical Center · Not applicable, Interventional, and Screening

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 2 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
500
Allocation
Not applicable
Ages
18 Years to 40 Years
Sex
Female
01

Study summary

The aim of the study is to examine the variation in blood pressure between an optimal measurement (according to established guidelines in the literature - per guidelines) and a 'common' measurement (used by nursing teams - per common practice) among women of reproductive age with and without hyperte

Read the detailed description

Accurate blood pressure measurement is a cornerstone of the diagnosis and management of hypertension. The latest Clinical Practice Guidelines (AHA2020- International Society of Hypertension Global) emphasize several important steps for accurate blood pressure measurement, including choosing the correct cuff size, resting for five minutes, sitting with support for the back, feet flat on the floor, and legs uncrossed, and proper arm positioning (i.e., positioning the midpoint of the cuff at heart level with the arm supported on a table or work surface). Sitting measurements are preferred because of the large amount of data linking blood pressure measurements in this position to health outcomes.

02

Conditions studied

  • Blood Pressure Measurement in Pregnancy
03

In context

Lead sponsor

Hillel Yaffe Medical Center is the lead sponsor of 305 studies on the registry; 10 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women aged 18-40
  • to participate.

Exclusion criteria

Exclusion Criteria:

  • Inability to cooperate with BP measurement under optimal conditions
  • Women with complex underlying disease that may bias the data (e.g. significant vasculopathy)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
500 participants (estimated)

Study arms

  • Experimental
    variation in blood pressure between an optimal measurement and a 'common' measurement

    Procedure: blood pressure measurement

Interventions

  • Procedureblood pressure measurement

    examine the variation in blood pressure between an optimal measurement (according to established guidelines in the literature - per guidelines) and a 'common' measurement (used by nursing teams - per common practice) among women of reproductive age with and without hypertention

06

What researchers measure

Primary outcomes

  1. Mean difference in systolic blood pressure (mmHg) between guideline-based and routine clinical measurement

    Mean difference in systolic blood pressure (mmHg) between guideline-based and routine clinical measurement Description: Systolic blood pressure (SBP) will be measured in each participant using two methods: 1. guideline-based blood pressure measurement performed according to international hypertension guidelines (seated position, appropriate cuff size, arm supported at heart level after ≥5 minutes of rest), and 2. routine clinical blood pressure measurement as performed by nursing staff under usual clinical conditions. The primary outcome will be the within-participant mean difference in SBP (mmHg) between the two measurement methods.

    Time frame: 1 year

Secondary outcomes

  1. Mean difference in diastolic blood pressure (mmHg) between guideline-based and routine clinical measurement

    As above, for diastolic blood pressure (DBP).

    Time frame: 1 year

  2. Mean difference in mean arterial pressure (mmHg) between guideline-based and routine clinical measurement

    Mean arterial pressure (MAP) will be calculated as MAP = (SBP + 2×DBP) / 3 for each measurement method. The outcome will be the within-participant difference between methods

    Time frame: 1 yaer

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2025 (actual). Primary completion is estimated for Aug 2026, 12 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 16, 2025
First posted
Jan 6, 2026
StartActual
Aug 24, 2025
Primary completionEst.
Aug 24, 2026
CompletionEst.
Aug 24, 2026
Last update
Jan 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07320339
Responsible party
Sponsor
First posted
Jan 6, 2026
Start date
Aug 24, 2025
Primary completion
Aug 24, 2026 (estimated)
Completion
Aug 24, 2026 (estimated)
Last update
Jan 6, 2026

Study contacts

Ikhlas IM Ammash, M.D
Contact
AnnaTu@hymc.gov.il
+972-4-7744602

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion